Search

Your search keyword '"Fekrazad M"' showing total 36 results
Start Over Author "Fekrazad M"
36 results on '"Fekrazad M"'

3. Contributors

Author

Ajaz, Mazhar, primary, Alexandru, Daniela, additional, Alongi, Filippo, additional, Ashworth, Allison, additional, Assouline, Avi, additional, Au, Joseph Siu-kie, additional, Bauman, Julie E., additional, Beomonte Zobel, Bruno, additional, Bhosle, Jaishree, additional, Bordi, Paola, additional, Bota, Daniela A., additional, Braverman, Albert S., additional, Calatozzolo, Chiara, additional, Chen, Yu-Hua, additional, Ciusani, Emilio, additional, Corsini, Elena, additional, De Bernardi, Bruno, additional, Di Meco, Francesco, additional, Errante, Yuri, additional, Fekrazad, M. Houman, additional, Fokas, Emmanouil, additional, Garaventa, Alberto, additional, Ghia, Amol J., additional, Hall, Walter A., additional, Huang, Jun, additional, Jones, Dennie V., additional, Joseph, Kurian, additional, Kalkanis, Steven N., additional, Komaki, Ritsuko, additional, Kong, Xiao-Tang, additional, Kundu, Supratip, additional, Li, Bo, additional, Li, Yan Michael, additional, Mallio, Carlo Augusto, additional, Mauri, Francesco A., additional, McDonald, Fiona, additional, Mubita, Lynn, additional, O’Brien, Mary, additional, Palma, David, additional, Pinato, David J., additional, Pollo, Bianca, additional, Quattrocchi, Carlo C., additional, Ray, Sayantan, additional, Ricardi, Umberto, additional, Rodrigues, George, additional, Sahgal, Arjun, additional, Sakellaridi, Lygeri, additional, Sakellaridis, Nikolaos, additional, Salmaggi, Andrea, additional, Sanaei, Omid, additional, Scorsetti, Marta, additional, Sekine, Akimasa, additional, Soliman, Hany, additional, Sonthalia, Nikhil, additional, Tai, Patricia, additional, Talukdar, Arunansu, additional, Tsao, May, additional, Vallera, Daniel A., additional, Wu, Shang-Gin, additional, Yu, Edward, additional, and Shih, Jin-Yuan, additional

Published
2014
Full Text
View/download PDF

11. Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer

Author

Araujo-Mino, Emilio P., primary, Patt, Yehuda Z., additional, Murray-Krezan, Cristina, additional, Hanson, Joshua A., additional, Bansal, Pranshu, additional, Liem, Ben J., additional, Rajput, Ashwani, additional, Fekrazad, M. Houman, additional, Heywood, Glenory, additional, and Lee, Fa Chyi, additional

Published
2017
Full Text
View/download PDF

12. Efficacy and safety of intravenous bisphosphonates beyond two years

Author

Gilliam, Eric H., Winters, John P., McGuire, Elizabeth A., Lee, Sang-Joon, Purdy, Malcolm, Fekrazad, M. Houman, Royce, Melanie E., and Choi, Kook I.

Subjects
Diphosphonates -- Health aspects, Bone diseases -- Care and treatment, Bone diseases -- Diagnosis, Health
Abstract

Background: Metastatic bone disease, a common complication of malignancy, causes significant morbidity in affected patients. Intravenous bisphosphonates (IBPs) have shown efficacy in preventing skeletal morbidity, however few studies have investigated their efficacy and safety in cancer patients beyond 2 years of use. This retrospective study documents long term clinical use of IBPs among a variety of patient populations and clinical settings. Methods: This study is a multi-center retrospective chart review of patients who received IBPs (Pamidronate or Zoledronic Acid) for more than 24 months. Patients were at least 18 years of age and had tumor-associated bone disease. Data analysis focused on skeletal related events (SREs) and drug related toxicities such as renal failure and osteonecrosis of the jaw (ONJ). Results: Ninety-two patients were included with the most common diagnosis being multiple myeloma. A total of 44 SREs occurred among 23 patients. Mean time to first SRE was 515 days. The rate of skeletal events in the first 2 years of treatment was 0.70, while skeletal morbidity rate (SMR) in subsequent years was 0.16. Thirteen patients experienced renal toxicity; most patients' renal function normalized after brief or permanent cessation of IBP therapy. ONJ was associated with 5 patients. Conclusion: Continuation of IBP therapy for skeletal metastasis after 2 years of treatment may improve skeletal morbidity. Similar to the first 2 years of treatment, significant toxicities such as renal failure and ONJ are uncommon. Keywords: Bisphosphonates | metastatic bone disease | safety, Introduction Bone metastasis leads to significant morbidity, such as bone pain, pathologic fractures, spinal cord compression, and hypercalcemia of malignancy. (1,2) Optimal management of bone metastasis is important as it [...]

Published
2010

13. Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer.

Author

Araujo‐Mino, Emilio P., Patt, Yehuda Z., Murray‐Krezan, Cristina, Hanson, Joshua A., Bansal, Pranshu, Liem, Ben J., Rajput, Ashwani, Fekrazad, M. Houman, Heywood, Glenory, and Lee, Fa Chyi

Subjects
ANAL surgery, RECTUM tumors, THERAPEUTIC use of antimetabolites, ANTIMETABOLITES, CANCER patients, CLINICAL trials, COMBINED modality therapy, CONFIDENCE intervals, DIARRHEA, DRUG tolerance, LIVER, NONSTEROIDAL anti-inflammatory agents, RECTAL diseases, SKIN inflammation, SURVIVAL, CYCLOOXYGENASE 2, OXALIPLATIN, TREATMENT effectiveness, CHEMORADIOTHERAPY, DIAGNOSIS, PROGNOSIS, THERAPEUTICS, TUMOR treatment
Abstract

Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2018
Full Text
View/download PDF

14. Human Papilloma Virus-Induced Head and Neck Cancer

Author

Dennie V. Jones, Julie E. Bauman, and Houman Fekrazad M

Subjects
Cervical cancer, medicine.medical_specialty, business.industry, Incidence (epidemiology), Head and neck cancer, Cancer, Esophageal cancer, medicine.disease, Omics, medicine.anatomical_structure, Otorhinolaryngology, Internal medicine, Tonsil, Immunology, medicine, business
Abstract

Head and neck cancers are a common spectrum of diseases, accounting for over one-third of a million deaths worldwide each year, and over 11,000 annual US deaths. Most head and neck cancers have traditionally been diagnosed in older males who abuse tobacco and/or alcohol. With increasing public awareness of the dangers of tobacco exposure and excessive alcohol intake, the incidence of many subgroups of head and neck cancer is now decreasing in the West. However, over the past several decades, the rates of carcinomas of the tonsil and base of tongue are increasing, and are affecting a different demographic group consisting mainly of younger, nonsmoking, males. These lesions are caused by infections with the same high-risk human papillomaviruses (HPV) genotypes as those responsible for cervical cancer and other anogenital neoplasms. These HPV-induced head and neck cancers differ in their biology and prognosis from those neoplasms induced by tobacco or ethanol. Understanding the biology of these lesions will allow for the development of selective preventive and treatment strategies, and better outcomes, for this subpopulation of patients.

Published
2012

23. Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC).

Author

Bauman, Julie E., primary, Arias-Pulido, Hugo, additional, Lee, Sang-Joon, additional, Considine, Michael, additional, Fekrazad, M Houman, additional, Howard, Jason, additional, Bishop, Justin A., additional, Olson, Garth T, additional, Jones, Dennie V., additional, Fertig, Elana J., additional, and Chung, Christine H., additional

Published
2012
Full Text
View/download PDF

29. Clinicopathologic Features of Agranulocytosis in the Setting of Levamisole-Tainted Cocaine

Author

Czuchlewski, David R., primary, Brackney, Monica, additional, Ewers, Christina, additional, Manna, Jonaki, additional, Fekrazad, M. Houman, additional, Martinez, Afton, additional, Nolte, Kurt B., additional, Hjelle, Brian, additional, Rabinowitz, Ian, additional, Curtis, Brian R., additional, McFarland, Janice G., additional, Baumbach, Joan, additional, and Foucar, Kathryn, additional

Published
2010
Full Text
View/download PDF

33. Agranulocytosis Associated with Cocaine Use -- Four States, March 2008-November 2009.

Author

Brackney, M., Baumbach, J., Ewers, C., Martinez, A. L., Hagan, J., Czuchlewski, D., Foucar, K., Fekrazad, M. H., Seifert, S. A., Rimple, D., Nolte, K. B., Buchanan, J. A., Lavonas, E. J., Nelson, C., Wood, R. W., Duchin, J. S., VanEenwyk, J., Reuter, N., Ta, M. L., and Vagi, S.

Subjects
CASE studies, AGRANULOCYTOSIS, COCAINE abuse, LEVAMISOLE, MEDICAL research
Abstract

The article discusses several cases of agranulocytosis associated with cocaine use in four U.S. states and Canadian provinces. The New Mexico Department of Health's (NMDOH) investigation revealed that several patients with agranulocytosis had levamisole, which is used as an additive to cocaine. Other areas with similar findings are Washington, British Columbia and Alberta.

Published
2009

34. Agranulocytosis Associated With Cocaine Use-- Four States, March 2008- November2009.

Author

Brackney, M., Baumbach, J., Ewers, C., Martinez, A. L., Hagan, J., Czuchlewski, D., Foucar, K., Fekrazad, M. H., Seifert, S. A., Rimple, D., Nolte, K. B., Buchanan, J. A., Lavonas, E. J., Nelson, C., Wood, R. W., Duchin, J. S., VanEenwyk, J., Reuter, N., Ta, M. L., and Vagi, S.

Subjects
COCAINE, AGRANULOCYTOSIS, COCAINE abuse, LEVAMISOLE, DISEASE risk factors
Abstract

The article discusses a report on the link between agranulocytosis and cocaine use in New Mexico and Washington from April 2008 to November 2009. The report, which was issued by the Centers for Disease Control and Prevention (CDC), discovered that 11 cases of unexplained agranulocytosis were associated with cocaine use. It summarized the findings of investigations in New Mexico and Washington, which claimed that the levamisole contents of cocaine is the likely cause of agranulocytosis. The report also described the prevalence of agranulocytosis in the states. Authors of the report emphasized the need to consider their findings in differential diagnosis of agranulocytosis.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results